| Ytd | -79.21% | |
| 1y | -85.70% |
| Open | 1.27 | Prev Close | 1.27 | Low | 1.27 | High | 1.27 | Mkt Cap | 387.11M |
| Vol | 1.59M | Avg Vol | 268.09K | EPS | -3.61 | P/E | N/A | Forward P/E | -2.71 |
| Beta | 0.19 | Short Ratio | 11.22 | Inst. Own | 63.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 12.15 | 200-d Avg | 10.57 | 1yr Est | 19.73 |
IGMS News
IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a bio
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Cons
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earni
IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on be
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on be
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on be
Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th f
Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with
BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2,
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achiev
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Compan
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Cons
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperf
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surgin
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reporte
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of
U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday.
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.
Tuesday saw 132 companies set new 52-week lows.
On Wednesday, 311 stocks hit new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
On Tuesday, 164 companies achieved new lows for the year.
During Monday's session, 201 stocks hit new 52-week lows.
During Tuesday's trading, 188 companies set new 52-week lows.
On Monday, 149 companies reached new 52-week lows.